Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

GlaxoSmithkline Pharmaceuticals Ltd (GLAX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2,106.00 +19.25    +0.92%
05:59:56 - Closed. Currency in INR ( Disclaimer )
Type:  Equity
Market:  India
ISIN:  INE159A01016 
S/N:  GLAXO
  • Volume: 60,821
  • Bid/Ask: 2,100.10 / 2,105.95
  • Day's Range: 2,078.80 - 2,124.00
GlaxoSmithkline Pharma 2,106.00 +19.25 +0.92%

GlaxoSmithkline Pharmaceuticals Ltd Company Profile

 
Get an in-depth profile of GlaxoSmithkline Pharmaceuticals Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

3840

Equity Type

ORD

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of Shingles and Post herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; TENOVATE and Flutivate for skin conditions to reduce inflammation; PHYSIOGEL for dry skin and dry skin associated with redness and itch; Zimig for fungal skin infections; COBADEX CZS, a multivitamin; and Supacef, a bactericidal cephalosporin antibiotic. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Contact Information

Address GSK House Dr. Annie Besant Road
Mumbai, 400030
India
Phone 91 22 2495 9595
Fax 91 22 2495 9494

Top Executives

Name Age Since Title
Renu Sud Karnad 70 2019 Non-Executive Chairperson
Damodarannair Sundaram 69 2009 Non-Executive Independent Director
Pradeep Vasudeo Bhide 72 2010 Non-Executive Independent Director
Subesh Williams 60 2017 Non Executive Director
Sunita Maheshwari 56 2020 Non-Executive & Independent Director
Juby Chandy - 2022 Whole-Time Director & CFO
Manu Anand 64 2022 Independent Director
Anami Narayan Prema Roy 74 2011 Non-Executive Independent Director
Bhushan Akshikar - 2020 MD & Executive Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GLAX Comments

Write your thoughts about GlaxoSmithkline Pharmaceuticals Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
soumitra saraswat
soumitra saraswat Jan 26, 2024 8:31AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
whats the target
Ladislav Cendelin
Ladislav Cendelin Feb 11, 2021 8:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://twitter.com/naturecosmopol2/status/1359644557927993345?s=20
Keval Mehta
Keval Mehta Jul 09, 2019 3:51PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
buy it at 1170 soon cross 1200
Virendra Shah
Virendra Shah May 23, 2018 2:01AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buy at 2350 may cross 4000
ILAYARAJAN RATHAKRISHNAN
rilayarajan May 23, 2018 2:01AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
How it will reach 4000 any specific reason??
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email